Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Go 6983 (also known as GOE-6983; Go-6983; GOE6983; Go6983) is a novel and potent pan-PKC (protein kinase C) inhibitor with potential anticancer and cardioprotective activity. It inhibits PKCα, PKCβ, PKCγ and PKCδ with IC50s of 7 nM, 7 nM, 6 nM and 10 nM, respectively. Go 6983 shows less potency against PKCζ and is inactive on PKCμ. GO6893 displays cardioprotective properties and can reduce polymorphonuclear leukocyte adherence and infiltration following myocardial ischemia/reperfusion injury. When tested with MCF-7 and T47D cells, Go 6983 showed reversible effect on the down-regulation of PKCαand PKCδ induced by PKC activator PDBu, while decreased the expression of PKCη which up-regulated by PDBu.
ln Vitro |
PKCu is inhibited by Go 6983, with an IC50 of 20 μM. Go 6983 has an IC50 of 7 to 60 nM and can inhibit PKC isoenzymes [1]. When compared to I/R + PMN hearts, Go 6983 (100 nM) significantly inhibited PMN superoxide emission by 90 +/-2% in rat hearts and significantly reduced PMN adherence to endothelial cells and infiltration into the myocardium. [2]. The cardioprotective impact of Go 6983 (200 nM) is less than that of Go 6983 (50 and 100 nM), despite the fact that it inhibits PMN superoxide production by 99% [3].
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
[1]. Gschwendt M, et al. Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett, 1996, 392(2), 77-80.
[2]. Peterman EE, et al. G0 6983 exerts cardioprotective effects in myocardial ischemia/reperfusion. J Cardiovasc Pharmacol, 2004, 43(5), 645-656. [3]. Young LH, et al. G0 6983: a fast acting protein kinase C inhibitor that attenuates myocardial ischemia/reperfusion injury. Cardiovasc Drug Rev, 2005, 23(3), 255-272 |
Molecular Formula |
C26H26N4O3
|
|
---|---|---|
Molecular Weight |
442.51
|
|
CAS # |
133053-19-7
|
|
SMILES |
O(C([H])([H])[H])C1C([H])=C([H])C2=C(C=1[H])C(C1C(N([H])C(C=1C1=C([H])N([H])C3=C([H])C([H])=C([H])C([H])=C13)=O)=O)=C([H])N2C([H])([H])C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])[H]
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2598 mL | 11.2992 mL | 22.5984 mL | |
5 mM | 0.4520 mL | 2.2598 mL | 4.5197 mL | |
10 mM | 0.2260 mL | 1.1299 mL | 2.2598 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.